Clinical trials: Immunoglobulin
Hypereosinophilic Syndrome
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
This is a 52-week, randomized, placebo-controlled, double-blind, parallel group, multicenter study of depemokimab in adults with uncontrolled HES receiving standard of care (SoC) therapy.
- Trial name
- DESTINY (NCT05334368)
- Testing
- Depemokimab
- Where
- 60 sites in United States, Argentina and 14 more
- Volunteers
- 110 people
- Sponsor
- GlaxoSmithKline
Colorectal Cancer
Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer
A phase 1b/2a study evaluating the combination of MM-151 + nal-IRI + 5-FU + Leucovorin in RAS/RAF wild-type Metastatic Colorectal Cancer.
- Trial name
- NCT02785068
- Testing
- MM-151, nal-IRI, Leucovorin
- Sponsor
- Merrimack Pharmaceuticals
Hepatocellular Carcinoma
A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib
This is a Phase 3 multicenter, randomized study evaluating the safety and efficacy of ramucirumab DP plus BSC as a double-blind, placebo-controlled (placebo plus BSC) comparison.
- Trial name
- REACH (NCT01140347)
- Testing
- Ramucirumab DP (IMC-1121B), BSC
- Where
- 146 sites in United States, Australia and 25 more
- Volunteers
- 565 people
- Sponsor
- Eli Lilly and Company
Colorectal Cancer, Head and Neck Cancer
Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib
This is an open-label, phase 1, non-randomised, non-controlled trial, carried out in two centres on patients with advanced cancer expressing EGFR.
- Conditions
- Colorectal Cancer, Head and Neck Cancer, Non Small Cell Lung Cancer (NSCLC)
- Trial name
- NCT00820417
- Testing
- Cetuximab/Gefitinib combination and/or monotherapy
- Where
- 2 sites in Belgium, Spain
- Volunteers
- 63 people
- Sponsor
- Harrison Clinical Research
Neoplasms
Dose-escalation Study of Lupartumab Amadotin (BAY1129980)
The purpose of this study is to evaluate: The side effects of BAY1129980 when given every 21 days different dose levels. Determine the dose level of BAY1129980 that should be tested in future clinical research studies.
- Trial name
- NCT02134197
- Testing
- Lupartumab Amadotin (BAY1129980)
- Where
- 15 sites in United States
- Volunteers
- 69 people
- Sponsor
- Bayer
IgA Nephropathy
Phase 2b Open-Label Repeat Kidney Biopsy Study
Assess impact of sibeprenlimab on IgA deposition and other histological endpoints in kidney tissue at Week 52 relative to baseline
- Trial name
- NCT06740526
- Testing
- Sibeprenlimab
- Where
- 19 sites in United States, Argentina and 3 more
- Volunteers
- 56 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Rectal Adenocarcinoma
A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma
This is a phase I study incorporating bavituximab into the care of patients with rectal adenocarcinoma simultaneously treated with capecitabine and radiation therapy.
- Trial name
- NCT01634685
- Testing
- Radiation, Bavituximab, Capecitabine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Texas Southwestern Medical Center
Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma
Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma
This phase II trial studies how well dinutuximab works when given with sargramostim in treating patients with osteosarcoma that has come back after treatment (recurrent).
- Conditions
- Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma, Recurrent Osteosarcoma
- Trial name
- NCT02484443
- Testing
- Dinutuximab, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 130 sites in United States, Australia and 3 more
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Anaplastic Large Cell Lymphoma
SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma
This phase II trial is studying how well giving SGN-30 together with combination chemotherapy works in treating patients with newly diagnosed anaplastic large cell lymphoma.
- Trial name
- NCT00365274
- Testing
- Cyclophosphamide, Doxorubicin hydrochloride, vincristine sulfate
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
B-cell Malignancies
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
This is a Phase I/II study designed to evaluate if experimental T cell engaging antibody targeting CD20 AZD5492 is safe, tolerable and efficacious in participants with Relapsed or Refractory B-Cell Malignancies.
- Trial name
- TITANium (NCT06542250)
- Testing
- AZD5492
- Where
- 31 sites in United States, Australia and 8 more
- Volunteers
- 174 people
- Sponsor
- AstraZeneca
Kidney Diseases
A Trial of Tolerogenic Immunosuppression in Highly Sensitized Renal Transplant Recipients
Comparison between Campath induction and monotherapy with Tacrolimus vs Thymoglobulin induction and triple drug maintenance using Tacrolimus, mycophenolate, and steroids.
- Trial name
- NCT00407160
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Ulcerative Colitis
A Dose-Escalation Study of MDX-1100 in Patients With Active Ulcerative Colitis
This is a Phase I dose-escalation study of MDX-1100. patients with ulcerative colitis will be enrolled into one of four dose cohorts, to receive of MDX-1100 at 0.3, 1.0, 3.0 or 10mg/kg.
- Trial name
- NCT00295282
- Testing
- MDX-1100 (anti-CXCL10 human monoclonal antibody)
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Bristol-Myers Squibb
Chronic Kidney Diseases, Inflammation
Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition
Patients with chronic kidney disease, who have evidence of systemic inflammation with increased cardiovascular risk, will be enrolled into this trial.
- Trial name
- RESCUE (NCT03926117)
- Testing
- Ziltivekimab
- Where
- 49 sites in United States
- Volunteers
- 264 people
- Sponsor
- Novo Nordisk A/S
Cancer, Neoplasms
Immuno Positron Emission Tomography Study of GSK2849330 in Subjects With Human Epidermal Growth Factor Receptor 3-Positive Solid Tumors
Human epidermal growth factor receptor 3 (HER3) expression is seen across a wide variety of solid malignancies and is associated with poor prognosis.
- Trial name
- NCT02345174
- Testing
- GSK2849330, 89Zr-GSK2849330
- Where
- 2 sites in Netherlands
- Volunteers
- 6 people
- Sponsor
- GlaxoSmithKline
PD-1 Antibody, CAR-T Cells
PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor
To evaluate the safety and effectiveness of cell therapy using herinCAR-PD1 cells to treat advanced cancer. Individuals greater than or equal to 18 years of age and less than or equal to 70 years of age who have been diagnosed…
- Conditions
- PD-1 Antibody, CAR-T Cells, Advanced Malignancies
- Trial name
- NCT02873390
- Testing
- HerinCAR-PD1 cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ningbo Cancer Hospital
Primary Amyloidosis
A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis
The treatment with oral melphalan and prednisone has been recommended as standard treatment of AL amyloidosis but the results are rather disappointing.
- Trial name
- LEOMEX (NCT00883623)
- Testing
- Lenalidomide
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Heidelberg University
Lung Cancer
Chest Computed Tomography (CT) Screening Study With Antibody Testing
The purpose of this study is to assess the value of EarlyCDT-Lung test and CT scan both in lung cancer detection and potential health economic outcomes.
- Trial name
- NCT01203579
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Mayo Clinic
Psoriatic Arthritis
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
This was a randomized, double-blind, active controlled, multicenter, parallel-group study evaluating secukinumab monotherapy and adalimumab monotherapy in approximately 850 patients with active psoriatic arthritis (PsA) who are…
- Trial name
- EXCEED 1 (NCT02745080)
- Testing
- Secukinumab, Adalimumab
- Where
- 156 sites in United States, Australia and 24 more
- Volunteers
- 853 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma (Skin Cancer)
Exploratory Study With Parallel Controls on the Safety and Efficacy of Neoadjuvant Low Branched-Chain Amino Acid Diet in Combination With Anti-PD-1 Monoclonal Antibody for Stage III Melanoma
1. Primary Objective: To evaluate the safety of a low branched-chain amino acid diet (60% of the normal dietary BCAA content) combined with anti-PD-1 monoclonal antibody as neoadjuvant therapy in patients with stage III melanoma…
- Trial name
- NCT07586891
- Testing
- Low Branched-Chain Amino Acid Diet
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Xijing Hospital
Acute Graft-versus-host Disease
MSCs Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant aGVHD
The purpose of this study is to compare the efficacy of CD25 monoclonal antibody and calcineurin inhibitors with or without mesenchymal stem cells (MSCs) in treating patients with steroid-resistant acute graft-versus-host disease…
- Trial name
- NCT02241018
- Testing
- CD25 monoclonal antibody, calcineurin inhibitors, MSCs
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Nanfang Hospital, Southern Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.